Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Slides:

Advertisements

Similar presentations

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Advertisements

LaCasce A et al. Proc ASH 2014;Abstract 293.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

CCO Independent Conference Highlights

Chen R et al. Proc ASH 2015;Abstract 518.

Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Reeder CB et al. ASCO 2009; Abstract (Poster)

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Exploring Early Combination Therapy in PAH

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Optimizing Use of Biological Agents in Ulcerative Colitis

Emerging Data on ACS Management From ACC

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

PAD Patients vs Post-ACS Patients:

Peripheral T-Cell Lymphoma in 2013

Metastatic Renal Cell Carcinoma

Optimizing the Treatment of Recurrent/Metastatic SCCHN

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

CDK4/6 Inhibitors in Breast Cancer:

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Jonathan W. Friedberg M.D., M.M.Sc.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Updates in Lymphoma From Recent Congresses

Efficacy and Safety of Edoxaban in Patients With AF and HF

Recent Advances in the Treatment of Lymphoma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Follicular lymphoma Every patient should be treated at diagnosis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Locally Advanced Lung Cancer

Non-Chemotherapy Combinations in CLL

Treatment of Locally Advanced Pancreatic Cancer

Selecting and Applying Chemotherapy

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Are We Making Progress in the Management of Huntington Disease?

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

Managing Anemia in Lower-Risk MDS

Preparing for Checkpoint Inhibitors in Breast Cancer

First-Line FCR: Effect of del(17p) on PFS and OS

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

New Paradigms in M0 CRPC.

Taking a Closer Look at Recurrent/Metastatic SCCHN

Real-World Evidence.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

My PAH Patient.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Translating Data From Trial to Practice

Presentation transcript:

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Introduction

The Current Treatment Algorithm for FL

The Current Treatment Algorithm for MZL

Treatment Options for MCL

Treatment Options for R/R WM

What Is the Goal of Therapy in iNHL?

AUGMENT: Study Design

AUGMENT: Patient Characteristics

PFS in the ITT Population by IRC

OS in Patients With FL (Prespecified Subgroup Analysis)

Safety Profile in the AUGMENT Trial: AEs of Interest

CHRONOS-1: Methods

CHRONOS-1 Results

CHRONOS-1: Response Evaluation by Independent Assessment

INNOVATETM: Study Schema

INNOVATETM: Efficacy Results

SAKK 35/03 Trial Design

SAKK 35/03 Efficacy Results

Complement A+B: Ofatumumab + Bendamustine vs Bendamustine Alone

CONTRALTO Trial: Baseline Characteristics

CONTRALTO Trial: Safety

CONTRALTO Trial: Best Overall Response

Acalabrutinib Monotherapy in R/R MCL

Acalabrutinib: Efficacy Results

Acalabrutinib: Safety Findings

Lenalidomide Following Autologous Transplantation: MCL 0208 Trial

MCL 0208 Trial: Efficacy Results

The Potential Relevance of the Recent Data on Current Practice in FL

The Concept of "Chemotherapy-Free" Strategies

The Impact of New Data on the MCL Paradigm

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)